Skip to content

PolitiKit

Lobbying by Moderna Biopharma Canada Corporation: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Moderna Biopharma Canada Corporation

Meetings this Parliament
2
With MPs
0
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Jun 9, 2026.

Registrations in effect

Consultant In effect since Jun 9, 2026 Receives government funding

Consultant Richard Maksymetz of Barrack Hill Public Affairs Inc.

Consultant lobbyists

  • Richard Maksymetz Former designated public office holder

    Formerly Chief of Staff, Office of the Minister, Finance Canada (2015–2018)

    Formerly Special Assistant, Office of the Leader of the Official Opposition, House of Commons (2007–2010)

    Formerly Special Assistant, Office of the Member of Parliament for Desnethé—Missinippi—Churchill River, House of Commons (2007–2007)

    Formerly Special Assistant, Office of the Minister, Transport Canada (2004–2006)

  • Richard Maksymetz Former designated public office holder

    Formerly Chief of Staff, Office of the Minister, Finance Canada (2015–2018)

    Formerly Special Assistant, Office of the Leader of the Official Opposition, House of Commons (2007–2010)

    Formerly Special Assistant, Office of the Member of Parliament for Desnethé—Missinippi—Churchill River, House of Commons (2007–2007)

    Formerly Special Assistant, Office of the Minister, Transport Canada (2004–2006)

Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prairies Economic Development Canada (PrairiesCan), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (4)
  • Communicating with government officials about pandemic and emergency planning, including the "Pandemic Preparedness Plan" being prepared by the Public Health Agency of Canada ("PHAC").
  • Communicating with government officials about vaccine production, more specifically opportunities to increase biomanufacturing capabilities in Canada, including at Moderna's facility in Laval, Québec.
  • Communicating with government officials about procurement polices and procedures (including, but not limited to, those maintained by the Departments of Health and Public Services and Procurement), more specifically policies and procedures pertaining to the development, procurement and distribution of vaccines, including Moderna's messenger ribonucleic acid ("mRNA") vaccines.
  • Communicating with government officials, in general, about pharmaceutical and biotechnology policies, including those related to innovation, research and development and messenger ribonucleic acid ("mRNA") biotechnology.

Registration 954762-385030-2. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Richard Maksymetz · Consultant

    • Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials about vaccine production, more specifically opportunities to increase biomanufacturing capabilities in Canada, including at Moderna's facility in Laval, Québec. Read more

    Communicating with government officials about procurement polices and procedures (including, but not limited to, those maintained by the Departments of Health and Public Services and Procurement), more specifically policies and procedures pertaining to the development, procurement and distribution of vaccines, including Moderna's messenger ribonucleic acid ("mRNA") vaccines.

    Communicating with government officials, in general, about pharmaceutical and biotechnology policies, including those related to innovation, research and development and messenger ribonucleic acid ("mRNA") biotechnology.

    Official report

  • Reported by Richard Maksymetz · Consultant

    • Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
    • Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
    Communicating with government officials about procurement polices and procedures (including, but not limited to, those maintained by the Departments of Health and Public Services and Procurement), more specifically policies and procedures pertaining to the development, procurement and distribution of vaccines, including Moderna's messenger ribonucleic acid ("mRNA") vaccines. Read more

    Communicating with government officials about vaccine production, more specifically opportunities to increase biomanufacturing capabilities in Canada, including at Moderna's facility in Laval, Québec.

    Communicating with government officials, in general, about pharmaceutical and biotechnology policies, including those related to innovation, research and development and messenger ribonucleic acid ("mRNA") biotechnology.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.